GlassScriptPhysician profile
Benjamin J Shepherd
NPI 1437741311
$1,502.03
in general payments reported to CMS, 2019-2025
22 companies · $37.74 in 2025
The $37.74 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2022: $414 · 2023: $529 · 2024: $153 · 2025: $37.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $274.96 | 2021-2024 | Farxiga, Breztri |
| Abbvie INC. | $212.34 | 2021-2023 | |
| Glaxosmithkline, LLC. | $153.49 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $138.46 | 2024 | Dexcom G7 Gss (161) |
| Lilly USA, LLC | $84.49 | 2021-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $68.40 | 2021-2025 | |
| Inari Medical, INC. | $67.47 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $65.62 | 2022-2023 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $63.53 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $46.21 | 2021-2022 | |
| Pfizer INC. | $43.01 | 2021 | |
| Exact Sciences Corporation | $35.37 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.94 | 2022-2023 | Xifaxan |
| Vbi Vaccine (Delaware) INC. | $32.57 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $23.78 | 2021 | |
| Boston Scientific Corporation | $20.74 | 2023 | Wavewriter Alpha Prime 16 |
| Astellas Pharma US INC | $20.39 | 2023 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.41 | 2022 | |
| Novo Nordisk INC | $16.34 | 2023 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $16.12 | 2023 | Livalo, Seglentis |
| Stimwave Technologies Incorporated | $13.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.